Pulling SEC filings + quote and writing the call…

MOLINA HEALTHCARE, INC.
Next earnings Jul 21, 2026 (after close) · consensus $1.45 EPS, $10.9B rev
Last earnings +1.3% on 2026-04-22
Medicaid premiums aren't keeping up with medical costs — earnings fell 60% — and at 22x there's no margin-of-safety on a recovery.
Revenue (FY2025) $45.4B · FY2025
Middling fundamentals and a rich price (~72% above fair value) leave little margin of safety — a wait-and-see.
Molina Healthcare is a government-sponsored managed-care insurer (Medicaid, Medicare, Marketplace) whose FY2025 captures the sector-wide margin squeeze. Membership and premiums kept growing — revenue rose 11.7% to $45.4B — but profitability collapsed: net income fell 60.0% to $472M, operating income dropped 54.2% to $781M, and diluted EPS fell 56.3% to $8.92. The cause is exactly what the 10-K warns about: 'medical expenses have risen higher than anticipated, and our capitation rates have not kept pace,' compressing medical margins. Operating margin is now razor-thin at 1.7% and net margin just 1.0%, the inherent reality of a high-volume, fixed-premium model.
The balance sheet absorbed the hit. Equity fell 9.5% to $4.07B while long-term debt rose 28.8% to $3.77B (2.83x liabilities/equity), and operating cash flow swung to -$535M (a 183.1% deterioration), though insurer operating cash flow is heavily timing-driven by premium/claims cycles. Management leaned into buybacks anyway — $1.00B repurchased, cutting shares 7.2% — a vote of confidence that the rate/cost gap is cyclical rather than permanent.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:50 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $27.8B | $32.0B | $34.1B | $40.6B | $45.4B |
| Gross profit | — | — | — | — | — |
| Operating income | $1.02B | $1.17B | $1.57B | $1.71B | $781M |
| Net income | $659M | $792M | $1.09B | $1.18B | $472M |
| Diluted EPS | $11.25 | $13.55 | $18.77 | $20.42 | $8.92 |
| Net margin | 2.4% | 2.5% | 3.2% | 2.9% | 1.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0001179929, latest 10-Q filed 2026-04-23) · EODHD · Proprietary analysis · as of 6/21/2026, 8:50:01 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2026-07-01 | ZORETIC RICHARD C Director | Award | 237.00 @ $232.55 | $55.1K |
| 2026-07-01 | WOLF DALE B Director | Award | 237.00 @ $232.55 | $55.1K |
| 2026-07-01 | Schapiro Richard M Director | Award | 237.00 @ $232.55 | $55.1K |
| 2026-07-01 | ROMNEY RONNA Director | Award | 237.00 @ $232.55 | $55.1K |
| 2026-07-01 | ORLANDO STEVEN J Director | Award | 237.00 @ $232.55 | $55.1K |
| 2026-07-01 | Lockhart Stephen H Director | Award | 237.00 @ $232.55 | $55.1K |
| 2026-07-01 | GROHOWSKI LEO P Director | Award | 237.00 @ $232.55 | $55.1K |
| 2026-07-01 | SOISTMAN FRANCIS S JR Director | Award | 237.00 @ $232.55 | $55.1K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1194 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.